{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T16:27:38Z","timestamp":1773073658353,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013123","name":"New Brunswick Health Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013123","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Myeloma Canada"},{"DOI":"10.13039\/501100000521","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Res Involv Engagem"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Over the last decade there has been considerable research into the treatment, management, and quality of life of people living with multiple myeloma. However, there has been limited investigation into topics deemed important to patients and caregivers within this community. We conducted a James Lind Alliance Priority Setting Partnership to establish the \u2018Top 10 Priorities for Myeloma Research\u2019, informed by patient and public partners.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A research team and steering group were established in 2019 to conduct the myeloma priority setting partnership. Steering group members included patients, caregivers, and healthcare providers who advised the research team and oversaw the scope of the project, grounded on their lived experience. Following the James Lind Alliance guidelines for identification and ranking of research questions, we used surveys and a virtual workshop to collect and prioritize questions posed by myeloma patients, caregivers, and healthcare providers across Canada.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The Top 10 list of priorities for myeloma research was finalized at the consensus-building workshop and encompassed questions related to diagnosis, treatment, management, and living well with myeloma. A final participant evaluation survey elicited a positive response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Interpretation<\/jats:title>\n                <jats:p>The myeloma priority setting partnership identified the research priorities of people living with myeloma, caregivers, and healthcare providers to inform clinical research on this disease going forward. This project underscores the importance of patient and public engagement in the identification of research questions, highlighting the concerns of people affected by myeloma to ultimately improve the lives of people living with this disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40900-023-00476-9","type":"journal-article","created":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T10:01:59Z","timestamp":1690624919000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["How should multiple myeloma research change in a patient-oriented world? Findings and lessons from the pan-Canadian myeloma priority setting partnership"],"prefix":"10.1186","volume":"9","author":[{"given":"Sarah","family":"Bridges","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Robichaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Ridgway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Reece","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorelei","family":"Dalrymple","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Sully","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Nason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trish","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Paine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne","family":"Gulliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Reiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,29]]},"reference":[{"issue":"9","key":"476_CR1","doi-asserted-by":"publisher","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","volume":"25","author":"H Ludwig","year":"2020","unstructured":"Ludwig H, Novis Durie S, Meckl A, Hinke A, Durie B. Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. Oncologist. 2020;25(9):e1406\u201313.","journal-title":"Oncologist"},{"key":"476_CR2","doi-asserted-by":"publisher","first-page":"5428","DOI":"10.1158\/1078-0432.CCR-16-0866","volume":"22","author":"O Landgren","year":"2016","unstructured":"Landgren O, Rajkumar SV. New developments in diagnosis, prognosis, and assessment of response in multiple myeloma. Clin Cancer Res. 2016;22:5428\u201333.","journal-title":"Clin Cancer Res"},{"key":"476_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410\u201327.","journal-title":"Lancet"},{"issue":"22","key":"476_CR4","doi-asserted-by":"publisher","first-page":"5419","DOI":"10.1158\/1078-0432.CCR-16-0625","volume":"22","author":"KC Anderson","year":"2016","unstructured":"Anderson KC. Progress and paradigms in multiple myeloma. Clin Cancer Res. 2016;22(22):5419\u201327.","journal-title":"Clin Cancer Res"},{"issue":"9449","key":"476_CR5","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/S0140-6736(04)17494-1","volume":"364","author":"N Partridge","year":"2004","unstructured":"Partridge N, Scadding J. The James Lind Alliance: patients and clinicians should jointly identify their priorities for clinical trials. Lancet. 2004;364(9449):1923\u20134.","journal-title":"Lancet"},{"issue":"12","key":"476_CR6","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1177\/0141076813493063","volume":"106","author":"I Chalmers","year":"2013","unstructured":"Chalmers I, Atkinson P, Fenton M, Firkins L, Crowe S, Cowan K. Tackling treatment uncertainties together: the evolution of the James Lind Initiative, 2003\u20132013. J R Soc Med. 2013;106(12):482\u201391.","journal-title":"J R Soc Med"},{"issue":"1","key":"476_CR7","doi-asserted-by":"publisher","first-page":"E278","DOI":"10.9778\/cmajo.20210046","volume":"10","author":"C Cuthbert","year":"2022","unstructured":"Cuthbert C, Nixon N, Vickers M, Samimi S, Rawson K, Ramjeesingh R, et al. Top 10 research priorities for early-stage colorectal cancer: a Canadian patient-oriented priority-setting partnership. CMAJ Open. 2022;10(1):E278\u201387.","journal-title":"CMAJ Open"},{"issue":"4","key":"476_CR8","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00432-022-04042-w","volume":"149","author":"R Klotz","year":"2023","unstructured":"Klotz R, Holze M, D\u00f6rr-Harim C, Grohmann E, Nied B, Lebert B, et al. Top 10 research priorities in colorectal cancer: results from the colorectal cancer priority-setting partnership. J Cancer Res Clin Oncol. 2023;149(4):1561\u20138.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"476_CR9","doi-asserted-by":"publisher","first-page":"e028119","DOI":"10.1136\/bmjopen-2018-028119","volume":"9","author":"S Aldiss","year":"2019","unstructured":"Aldiss S, Fern LA, Phillips RS, Callaghan A, Dyker K, Gravestock H, et al. Research priorities for young people with cancer: a UK priority setting partnership with the James Lind Alliance. BMJ Open. 2019;9(8):e028119.","journal-title":"BMJ Open"},{"issue":"9220","key":"476_CR10","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/S0140-6736(00)02351-5","volume":"355","author":"D Tallon","year":"2000","unstructured":"Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the research consumer. Lancet. 2000;355(9220):2037\u201340.","journal-title":"Lancet"},{"issue":"1","key":"476_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40900-015-0005-8","volume":"1","author":"S Crowe","year":"2015","unstructured":"Crowe S, Fenton M, Hall M, Cowan K, Chalmers I. Patients\u2019, clinicians\u2019 and the research communities\u2019 priorities for treatment research: There is an important mismatch. Res Involv Engag. 2015;1(1):1.","journal-title":"Res Involv Engag"},{"issue":"14","key":"476_CR12","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1002\/cncr.32128","volume":"125","author":"M Tsang","year":"2019","unstructured":"Tsang M, Le M, Ghazawi FM, Cyr J, Alakel A, Rahme E, et al. Multiple myeloma epidemiology and patient geographic distribution in Canada: a population study. Cancer. 2019;125(14):2435\u201344.","journal-title":"Cancer"},{"key":"476_CR13","unstructured":"James Lind Alliance. The James Lind Alliance Guidebook [Internet]. 2021. Available from: www.jla.nihr.ac.uk"},{"issue":"5","key":"476_CR14","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1111\/bjh.17946","volume":"196","author":"S Fowler","year":"2022","unstructured":"Fowler S, McLaughlin L, Bridges S, Robichaud M, Ridgway B, Reece D, et al. The future of myeloma research in Canada and beyond: results of a James Lind Alliance priority setting partnership. Br J Haematol. 2022;196(5):e52.","journal-title":"Br J Haematol"},{"key":"476_CR15","unstructured":"Oxford Blood Group. What matters most to people with multiple myeloma? Patient workshop outcomes [Internet]. 2022 Mar [cited 2023 Jul 12]. Available from: https:\/\/www.imm.ox.ac.uk\/news\/patient-priorities-guide-oxford-myeloma-research"},{"key":"476_CR16","unstructured":"Myeloma Canada. Myeloma Canada. 2022 [cited 2023 Jan 2]. Aldo Del Col Research Grant. Available from: https:\/\/myeloma.ca\/en\/clinical-trials-101-1\/research-initiatives\/aldo-del-col-research-grant"},{"issue":"1","key":"476_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40900-019-0174-y","volume":"6","author":"K Jongsma","year":"2020","unstructured":"Jongsma K, van Seventer J, Verwoerd A, van Rensen A. Recommendations from a James Lind Alliance priority setting partnership\u2014a qualitative interview study. Res Involv Engag. 2020;6(1):1\u201313.","journal-title":"Res Involv Engag"},{"issue":"1","key":"476_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40900-019-0174-y","volume":"6","author":"K Staley","year":"2020","unstructured":"Staley K, Crowe S, Crocker JC, Madden M, Greenhalgh T. What happens after James Lind Alliance priority setting partnerships? A qualitative study of contexts, processes and impacts. Res Involv Engag. 2020;6(1):1\u201310.","journal-title":"Res Involv Engag"},{"key":"476_CR19","unstructured":"Fordham FT, Candy B, McMillan S, Thakrar S, Noble B, Best S. Does current palliative and end of life care research match the priorities of patients, carers and clinicians? A grant mapping analysis of the UK Clinical Research Collaboration\u2019s Health Research Classification System dataset 2014. 2017."},{"key":"476_CR20","unstructured":"Canadian Cancer Society. Our research strategy [Internet]. 2023 [cited 2023 Jul 16]. Available from: https:\/\/cancer.ca\/en\/research\/our-research-strategy"},{"key":"476_CR21","doi-asserted-by":"crossref","unstructured":"Staley K, Crowe S, Crocker JC, Madden M, Greenhalgh T. What happens after James Lind Alliance priority setting partnerships? A qualitative study of contexts, processes and impacts. Res Involv Engag. 2020;6(1).","DOI":"10.1186\/s40900-020-00210-9"},{"key":"476_CR22","doi-asserted-by":"crossref","unstructured":"Gonzalez M, Ogourtsova T, Zerbo A, Lalonde C, Spurway A, Gavin F, et al. Patient engagement in a national research network: barriers, facilitators, and impacts. Res Involv Engag. 2023;9(1).","DOI":"10.1186\/s40900-023-00418-5"},{"key":"476_CR23","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/bjc.2012.28","volume":"106","author":"Y Martins","year":"2012","unstructured":"Martins Y, Lederman RI, Lowenstein CL, Joffe S, Neville BA, Hastings BT, et al. Increasing response rates from physicians in oncology research: a structured literature review and data from a recent physician survey. Br J Cancer. 2012;106:1021\u20136.","journal-title":"Br J Cancer"},{"issue":"2","key":"476_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2478\/jesr-2019-0011","volume":"9","author":"MJ S\u00e1","year":"2019","unstructured":"S\u00e1 MJ, Ferreira CM, Serpa S. Virtual and face-to-face academic conferences: comparison and potentials. J Educ Soc Res. 2019;9(2):35\u201345.","journal-title":"J Educ Soc Res"},{"key":"476_CR25","unstructured":"James Lind Alliance. Making a difference. 2020 [cited 2021 Aug 9]. Working with the priorities. Available from: https:\/\/www.jla.nihr.ac.uk\/making-a-difference\/working-with-the-priorities.htm"},{"key":"476_CR26","unstructured":"James Lind Alliance. Making a difference. 2020 [cited 2021 Aug 9]. Funded Research. Available from: https:\/\/www.jla.nihr.ac.uk\/making-a-difference\/funded-research.htm"},{"key":"476_CR27","unstructured":"Whiting C. Evidently Cochrane. [cited 2021 Aug 9]. Priority Setting Partnerships: celebrating 16\u00a0years of work to reduce research waste. Available from: https:\/\/www.evidentlycochrane.net\/priority-setting-partnerships-celebrating-16-years-of-work-to-reduce-research-waste\/"},{"key":"476_CR28","unstructured":"Canadian Frailty Network. Research and KT. 2018 [cited 2021 Aug 9]. 2018 Catalyst Grant Competition. Available from: https:\/\/www.cfn-nce.ca\/research\/our-research\/our-portfolio-by-grant-type-or-competition\/2018-catalyst-grant-program\/"}],"container-title":["Research Involvement and Engagement"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40900-023-00476-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40900-023-00476-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40900-023-00476-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T10:05:01Z","timestamp":1690625101000},"score":1,"resource":{"primary":{"URL":"https:\/\/researchinvolvement.biomedcentral.com\/articles\/10.1186\/s40900-023-00476-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,29]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["476"],"URL":"https:\/\/doi.org\/10.1186\/s40900-023-00476-9","relation":{},"ISSN":["2056-7529"],"issn-type":[{"value":"2056-7529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,29]]},"assertion":[{"value":"14 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All phases of this study were reviewed and approved by the Horizon Health Network Human Research Protection Program including the Research Ethics Board. Informed consent was obtained from participants before each survey and the consensus-building workshop.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DR reports consultancy for and honoraria and research funding from Janssen, Celgene, a Bristol-Myers Squibb company, Amgen, Takeda, serving on board of directors or advisory committee for Janssen and Celgene, a Bristol-Myers Squibb company, honoraria and research funding from Merck and research funding from Otsuka; TR reports contracts with AstraZeneca, Roche, Pfizer, Amgen and BristolMyersSquibb; KS reports honoraria and research funding from Celgene, a Bristol-Myers Squibb company, Janssen, Amgen, Takeda; LD, DR, TR and WP are members of the Myeloma Canada Board of Directors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}